The bill amends RCW 42.56.360 to exempt information related to collaborative drug therapy agreements from public disclosure under the Public Records Act. Specifically, it introduces new provisions that classify the contents of these agreements, as determined by the pharmacy quality assurance commission, as confidential. The bill allows for disclosure of such agreements only if they are the basis for a disciplinary action against a license holder, while ensuring that personally identifiable information of individuals other than the disciplined license holder remains confidential.

Additionally, the bill defines "personally identifiable information" to include names, mailing addresses, credential numbers, email addresses, and contact information for practice sites. This amendment aims to protect sensitive information while still allowing for accountability in cases of misconduct related to collaborative drug therapy agreements. Overall, the bill seeks to balance the need for transparency in healthcare practices with the necessity of safeguarding private information.

Statutes affected:
Original bill: 42.56.360